publication date: Mar. 16, 2018

Clinical Roundup ASTRO issues updated clinical guideline for whole breast radiation therapy

The American Society for Radiation Oncology issued a clinical guideline for the use of whole breast radiation therapy for breast cancer that expands the population of patients recommended to receive accelerated treatment known as hypofractionated therapy.

With hypofractionated WBI, patients receive larger doses of radiation across fewer treatment sessions—typically completing treatment in three to four weeks, compared with five to seven weeks for conventional treatment.

Reflecting current evidence from clinical trials and large cohort studies, the new guideline recommends hypofractionated WBI for breast cancer patients regardless of age, tumor stage and whether they have received chemotherapy. It replaces the existing ASTRO WBI guideline published in 2011.

“Previously, accelerated treatment was recommended only for certain patients, including older patients and those with less advanced disease, but recent long-term results from several large trials strongly support the safety and efficacy of accelerated treatment for most breast cancer patients,” said Benjamin Smith, co-chair of the guideline task force and an associate professor of radiation oncology at the University of Texas MD Anderson Cancer Center in Houston. “Conventional therapy does not provide an incremental benefit in either tumor control or side effects compared to hypofractionated WBI.”

Despite the data supporting accelerated treatment, large numbers of eligible breast cancer patients … Continue reading ASTRO issues updated clinical guideline for whole breast radiation therapy

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.